Spike Protein News and Research

RSS

Dutch study compares mRNA vaccines to vector-based vaccines for COVID-19

An overview of the PIENTER-Corona (PiCo) study, which is a Dutch nationwide efficacy comparison study on four different COVID-19 vaccines.

2 Nov 2021

The pros and cons of a COVID-19 vaccine booster

The authors provide an overview of current literature available to assess the need for COVID-19 vaccine booster doses and their potential target population.

2 Nov 2021

Humoral and cell-mediated immunity six months post BNT162b2 vaccination

A recent study has evaluated vaccine-induced humoral and cellular immunity against SARS-CoV-2 six months post BNT162b2 (Pfizer-BioNTech) vaccination.

2 Nov 2021

Trends in SARS-CoV-2 seroprevalence in Massachusetts

A new study reported findings from a retrospective, de-identified and systematic survey of SARS-CoV-2 seroprevalence among childbearing women in Massachusetts.

2 Nov 2021

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

A new study aimed to identify several potent neutralizing RBD-directed and NTD-directed mAbs that used a nanoparticle displaying the S glycoprotein to capture SARS-CoV-2-specific B cells.

2 Nov 2021

Identification of common genes in COVID-19 and COPD

Based on protein-protein interactions, the paper shows the presence of ten genes that overlap between the two illnesses, also shared by several other deadly and debilitating diseases.

2 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021

Study reassures the safety, immunogenicity of COVID-19 vaccines for patients with rheumatic diseases

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that the COVID-19 vaccine was not associated with severe disease flares in patients with rheumatic diseases.

1 Nov 2021

Evidence antibodies targeting HCoV-OC43 are robustly boosted in response to SARS-CoV-2 but not vaccination

The magnitude of cross-reactive antibodies correlated well with responses to the SARS-CoV-2 spike protein and the S2 subdomain.

1 Nov 2021

SARS-CoV-2 antibodies persisting for nearly a year, including to delta: NZ study

A cohort study found that antibodies to the SARS-CoV-2 spike protein and neutralizing antibodies remain relatively stable 8-11 months post-infection.

1 Nov 2021

COVID-19 antibody levels stay more durable in vaccinated people with prior SARS-CoV-2 infection

In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.

1 Nov 2021

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

The researchers investigated the neutralizing activity of turmeric root extract, curcumin-containing capsules, and pure curcumin against SARS-CoV-2.

1 Nov 2021

Identification of novel nanobodies to specifically target SARS-CoV-2 replication protein

Researchers have recently identified two nanobodies that show specific binding against a SARS-CoV-2 replication protein.

1 Nov 2021

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

A recent study published in the journal Cellular & Molecular Immunology shows that a new A.30 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can evade vaccine-induced antibodies and might spread outside the lungs extraordinarily well, with important implications for our public health response.

1 Nov 2021

Spike Protein News and Research

Dutch study compares mRNA vaccines to vector-based vaccines for COVID-19

The pros and cons of a COVID-19 vaccine booster

Humoral and cell-mediated immunity six months post BNT162b2 vaccination

Trends in SARS-CoV-2 seroprevalence in Massachusetts

Isolation of potent neutralizing monoclonal antibodies using nanoparticles displaying SARS-CoV-2 S glycoprotein

Identification of common genes in COVID-19 and COPD

SARS-CoV-2 variants neutralized by camel nanobodies

Study reassures the safety, immunogenicity of COVID-19 vaccines for patients with rheumatic diseases

Evidence antibodies targeting HCoV-OC43 are robustly boosted in response to SARS-CoV-2 but not vaccination

SARS-CoV-2 antibodies persisting for nearly a year, including to delta: NZ study

COVID-19 antibody levels stay more durable in vaccinated people with prior SARS-CoV-2 infection

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

Identification of novel nanobodies to specifically target SARS-CoV-2 replication protein

Emerging SARS-CoV-2 variant A.30 efficiently evades vaccine-induced immunity

The impact of SARS-CoV-2 variants on the COVID-19 epidemic in South Africa

Study uncovers unknown effects of COVID-19 virus on the immune system

How long does natural or vaccine-induced immunity to COVID last?

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

Study finds one mRNA vaccine dose after SARS-CoV-2 infection produces highest neutralizing antibody titers

Panel of broadly neutralizing SARS-CoV-2 nanobodies for immune assay application

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News